article thumbnail

Novartis’ Pluvicto presents survival benefit for castration-resistant prostate cancer

pharmaphorum

A vast majority of patients diagnosed with CRPC already present with metastases at the time of diagnosis. The findings will be presented at an upcoming medical meeting and submitted to the FDA for regulatory approval in 2023. Prostate cancer is the most frequently diagnosed cancer in men in 112 countries.

article thumbnail

Pluvicto™ offers survival benefits for metastatic prostate cancer

European Pharmaceutical Review

PSMAfore, is a Phase III, open-label, multi-centre, 1:1 randomised study comparing the efficacy and safety of Pluvicto to a change in ARPI in 469 patients with PSMA–positive mCRPC. Pluvicto is an intravenous radioligand therapy that combines a ligand, a targeting compound with lutetium-177, a therapeutic radionuclide.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The Wholesaling Prohibition (Potentially) Demystified? FDA’s Take on Supply Chains for Section 503B Outsourcing Facilities

The FDA Law Blog

As a reminder, in Title I of the 2013 Drug Quality and Security Act (DQSA) (the Compounding Quality Act), Congress created the “outsourcing facility” FDA registration category, and set forth statutory parameters for their operation in new section 503B of the FDCA. See 21 U.S.C. 353b(a)(8). 353b(a)(8).

article thumbnail

Ferrous Gluconate vs. Ferrous Sulfate: What’s the Difference?

BuzzRx

Remember that iron is present as a food additive in many foods like cereals. How to read iron supplement labels? If you have iron deficiency anemia and are taking iron supplements to get enough iron, you will notice that there are two amounts indicated on the label. The 325 mg refers to the ferrous sulfate compound.

article thumbnail

The hospital pharmacy landscape in 2024

Hospital Pharmacy Europe

These will undoubtedly present great opportunities for hospital pharmacists and their teams. We have just stepped into a new year, and it is already clear that the pharmacy landscape is set to experience significant innovations and challenges over the coming weeks and months.

Hospitals 111
article thumbnail

Collaboration with Janssen and Eli Lilly to address lack of paediatric medications

Pharmaceutical Technology

Therefore, with an inadequate or loss of response to these anti-TNFs, clinicians must prescribe adult therapies off-label to treat younger patients. This lack of options and progression within this IBD patient subpopulation presents a clear unmet need and opportunity.

article thumbnail

Entrance of novel therapies will drive Niemann-Pick type C disease market growth

Pharmaceutical Technology

The three major markets (3MM: the US, Germany and the UK) will increase in market size from $128.35m last year to $188.35m in 2031, at a compound annual growth rate (CAGR) of 3.9%. This sales growth will be in line with a steadily increasing disease prevalence and the entrance of novel agents into the market.